TRIMBOW (bromure de glycopyrronium/ dipropionate de béclométasone/ fumarate de ...)

PULMONOLOGY - New medicinal product

Opinions on drugs - Posted on Apr 03 2020

Reason for request

Re-assesment of the Clinical benefit

Moderate clinical benefit in the treatment of adult patients with severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA) or a combination of a long-acting beta2-agonist and a long-acting muscarinic antagonist (LAMA) and no demonstrated clinical added value in the care pathway

Insufficient clinical benefit in the treatment of moderate COPD

TRIMBOW has an MA for maintenance treatment in adult patients with moderate to severe COPD who are not adequately treated by a combination of an ICS and a LABA or a combination of a LABA and a LAMA.
It simplifies the treatment of patients with severe disease, requiring triple inhaled therapy combining two long-acting bronchodilators (LABA + LAMA) with an ICS.
TRIMBOW was statistically superior to an ICS/LABA or LAMA/LAMA combination for the occurrence of exacerbations, the forced expiratory volume per second (FEV₁) and quality of life, but the differences were modest.